News

Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...
BioWorld2d

Response’s RDX-002 staves off weight rebound after GLP-1 course

Taking weight off with a glucagon-like peptide-1 (GLP-1) receptor agonist and keeping it off once the drug has been discontinued has been a tall order but Response Pharmaceuticals Inc. is seeing ...
Applied Clinical Trials Online1d

Response’s Investigational Small Molecule Inhibitor Shows Promising Post-GLP-1 Weight Management, Cardiometabolic Benefits

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...
The Pharma Letter1d

Response offers positive Phase II data for post-GLP-1 obesity

US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...
Clinical Trials Arena on MSN1d

Response’s post-GLP-1RA drug reduces weight rebound in Phase II

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.
Fierce Biotech2d

Response's ex-Sanofi asset hits midphase goal in post-GLP-1 patients

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...
BioWorld2d

A-T competitors line up; Intrabio, Niagen, Quince boast prospects

Among the prominent players are Intrabio Inc., Niagen Bioscience Inc., and Quince Therapeutics Inc. Typically, A-T is first diagnosed before the age of 5 as children begin to develop an altered gait.
Consumer Reports1d

2013 Acura RDX Reviews, Ratings, Prices - Consumer Reports

Get the latest in-depth reviews, ratings, pricing and more for the 2013 Acura RDX from Consumer Reports.